In order to assess whether the aggregation of B cells derived from MS patients could be inhibited by using anti-CEACAM1 antibody we used the human in vitro B cell aggregation assay as initially described by Lobo et al. 18 (Fig. 5A, both panels). The gene discussed is CEACAM1; the disease is myeloid sarcoma.